18 assets in Peritoneal Neoplasm

Therapeutic assets addressing Peritoneal Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Peritoneal Neoplasm	Eli Lilly and Company	P3	BBB (74)
Adriamycin Peritoneal Neoplasm	Eli Lilly and Company	P3	BBB (72)
Nogitecan Peritoneal Neoplasm	Eli Lilly and Company	P3	BB (64)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone Peritoneal Neoplasm	Corcept Therapeutics	P3	BB (64)
Olaparib Peritoneal Neoplasm	Merck Sharp & Dohme LLC	P3	B (63)
Docetaxel Peritoneal Neoplasm	Clinica Universidad de Navarra, Universidad de Navarra	P3	B (62)
Oxaliplatin Peritoneal Neoplasm	Sun Yat-sen University	P2/3	B (62)
Pembrolizumab Peritoneal Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P3	B (62)
Mirvetuximab Soravtansine Peritoneal Neoplasm	Eli Lilly and Company	P3	B (60)
Sofetabart Mipitecan Peritoneal Neoplasm	Eli Lilly and Company	P3	B (60)
Letrozole Peritoneal Neoplasm	Swiss GO Trial Group	P3	B (57)
Nilotinib Peritoneal Neoplasm	National Cancer Institute (NCI)	P2	B (57)
Durvalumab Peritoneal Neoplasm	AstraZeneca	P1/2	CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Peritoneal Neoplasm	AstraZeneca	P1/2	CCC (53)
Lorigerlimab Peritoneal Neoplasm	MacroGenics	P2	CCC (53)
Oregovamab Peritoneal Neoplasm	CanariaBio Inc.	P3	CCC (51)
ab-1015 Peritoneal Neoplasm	Arsenal Biosciences, Inc.	P1	CC (41)
Felmetatug Vedotin Peritoneal Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P1	CC (41)